Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

00420 224 910 672

(from 09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

00420 224 910 672

(09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Press release: Global lifesciences partner ELC Group teams with PSR Group for advanced drug development

ELC Group selects Pharma Scientific Research
(PSR Group) for initial commission of 10 new products

Cambridge, UK, 24th January 2017: Global life sciences partner ELC Group is teaming with New Zealand-based research and development company Pharma Scientific Research (PSR Group) to create highly advanced products for the pharmaceutical market.

Under the initial terms of the partnership, ELC Group has commissioned PSR Group to develop 10 new products for human use, targeting therapeutic areas including oncology, pain management, antibiotics, antibacterials, cardiovascular and diabetes.

ELC Group is commissioning the new products based on its Concept to Commercialisation process, with plans to market the products in key regions including the US, Europe, Latin America, Russia, the Middle East and China. The first product from this partnership is expected to be delivered in late 2017.

Through its collaboration with the University of Auckland, PSR Group harnesses state-of-the-art lab facilities and skilled scientists to develop advanced products – from solids and semi-solids to suspension and small injectibles, through to drug delivery systems and advanced therapies.

PSR Group’s research and development programme will harness the University of Auckland’s own inventions, technologies and delivery platforms and combine them with its own research to create highly advanced pharmaceutical products for ELC Group.

The University of Auckland – New Zealand’s largest university and consistently ranked in the world’s top one percent of institutions for clinical, pre-clinical and health research – specialises in advanced therapies for oncology and opthalmics, plus the development of drug delivery platforms that combine drug and medical devices, including nano and liposome solutions.

ELC Group CEO Marco Rubinstein commented: “PSR Group was the stand-out choice as our drug development partner, due to the company’s significant skills and expertise, plus its unique access to key scientific resources at the University of Auckland.”

He added: “The move into drug development is a natural progression for ELC Group, based on increasing demand for a broader range of services from our long-term clients. Our business now spans the entire pharmaceutical process, from planning and developing new products, to registration and commercialisation of products in differently developed markets of the world.”

Akhil Jain, CEO of PSR Group, said: “PSR Group is building a world-class capability for the development of technically challenging, proprietary and generic pharmaceutical products. We are excited to be working together to create an exceptional portfolio of products that can be introduced into the market via ELC Group’s proven commercialisation process and deliver long-term impact on health outcomes.”

– Ends –

About ELC Group

ELC GROUP is a fully-fledged global regulatory, clinical and lifesciences partner, working with major pharmaceutical stakeholders for over a decade.

From Concept to Commercialisation is one of the key partnership areas in which ELC GROUP is creating its fast-growing success. From the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product, ELC GROUP aligns itself as a strategic partner to help pharmaceutical companies achieve their healthcare goals.

ELC GROUP’s worldwide network of professionals spans all major lifescience and Regulatory Affairs services across the key healthcare vertical markets of Pharmaceuticals, Biotech, Clinical, Consumer Healthcare, Medical Devices, Nutraceuticals and Veterinary. The team ranges from former FDA investigators to individuals with over 30 years of industry experience and broad capabilities, including in the areas of integrated advanced technologies, Regulatory Affairs consulting and commercialisation services.

ELC GROUP works with equal success in partnership with large multi-nationals, small enterprises and start-ups, biotechs, CROs and device manufacturers.